(Q39938769)

1 July 2019

title

Effects of raloxifene on breast cancer cell migration and invasion through the actin cytoskeleton (English)

1 reference

1 July 2019

0 references

10

1 reference

PubMed publication ID

15 September 2017

Marina Ines Flamini

1

1 reference

1 July 2019

Xiao-Dong Fu

2

1 reference

1 July 2019

Angel Matias Sanchez

3

1 reference

1 July 2019

Maria Silvia Giretti

4

1 reference

1 July 2019

Silvia Garibaldi

5

1 reference

1 July 2019

Lorenzo Goglia

6

1 reference

1 July 2019

Silvia Pisaneschi

7

1 reference

1 July 2019

Veronica Tosi

8

1 reference

1 July 2019

Andrea Riccardo Genazzani

9

1 reference

1 July 2019

publication date

1 August 2009

1 reference

1 July 2019

Journal of Cellular and Molecular Medicine

published in

1 reference

1 July 2019

volume

13

1 reference

1 July 2019

issue

8B

1 reference

1 July 2019

page(s)

2396-2407

1 reference

1 July 2019

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

Actin polymerization machinery: the finish line of signaling networks, the starting point of cellular movement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

ERM proteins: from cellular architecture to cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

Ezrin/moesin in motile Walker 256 carcinosarcoma cells: signal-dependent relocalization and role in migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

Non-genomic actions of sex steroid hormones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

Estrogen carcinogenesis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

Tamoxifen: a most unlikely pioneering medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

Cellular motility driven by assembly and disassembly of actin filaments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

Effects of raloxifene hydrochloride on endometrial cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

Ezrin, a key component in tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

Selective estrogen receptor modulators accelerate cutaneous wound healing in ovariectomized female mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00505.X

Raloxifene: bone and cardiovascular effects

21 January 2018

1 reference

12 December 2020

Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway

1 reference

12 December 2020

Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro

1 reference

12 December 2020

1 reference

12 December 2020

Ezrin: a protein requiring conformational activation to link microfilaments to the plasma membrane in the assembly of cell surface structures

1 reference

12 December 2020

Phosphorylation of moesin by rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures

1 reference

12 December 2020

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

10.1111/J.1582-4934.2008.00505.X

Identifiers

DOI

1 reference

1 July 2019

release_txt7dcotmfh3tc4a3rot5qw2my

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/txt7dcotmfh3tc4a3rot5qw2my

24 November 2022

mapped directly with Wikidata item

PMC publication ID

6512380

1 reference

1 July 2019

PubMed publication ID

18798864

1 reference

1 July 2019